Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

DEEPIKA PULUSANI

NPI
1306937438
CMS profile
149764
Location
MEMPHIS, TN

General Payments · PY2018–2024

$1,441.88

  • Reported across 61 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$236.61

14 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $197.37 10
Education $39.24 4

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Fresenius USA Marketing, Inc. $124.48 6
Retrophin, Inc. $63.62 5
CorMedix Inc. $19.43 1
Ardelyx, Inc. $14.77 1
Bayer HealthCare Pharmaceuticals Inc. $14.31 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $180.33 11
PY2019 $214.18 9
PY2020 $67.28 4
PY2021 $389.84 8
PY2022 $60.92 4
PY2023 $292.72 11
PY2024 $236.61 14

Payment records · PY2024 (14)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Ardelyx, Inc. $14.77 08/08/2024 Food and Beverage Undisputed 01/23/2026 1146701852 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.31 04/09/2024 Food and Beverage Undisputed 01/23/2026 1086217909 CMS
CorMedix Inc. $19.43 11/27/2024 Food and Beverage Undisputed 01/23/2026 1082026610 CMS
Fresenius USA Marketing, Inc. $17.70 01/24/2024 Food and Beverage Undisputed 01/23/2026 1154208796 CMS
Fresenius USA Marketing, Inc. $23.73 03/11/2024 Food and Beverage Undisputed 01/23/2026 1154208806 CMS
Fresenius USA Marketing, Inc. $20.21 04/08/2024 Food and Beverage Undisputed 01/23/2026 1154208800 CMS
Fresenius USA Marketing, Inc. $22.08 04/24/2024 Food and Beverage Undisputed 01/23/2026 1154208802 CMS
Fresenius USA Marketing, Inc. $18.67 07/08/2024 Food and Beverage Undisputed 01/23/2026 1154208798 CMS
Fresenius USA Marketing, Inc. $22.09 09/09/2024 Food and Beverage Undisputed 01/23/2026 1154208804 CMS
Travere Therapeutics, Inc. $3.08 01/30/2024 Education Undisputed 01/23/2026 1149932566 CMS
Travere Therapeutics, Inc. $16.89 01/30/2024 Education Undisputed 01/23/2026 1149932569 CMS
Travere Therapeutics, Inc. $16.89 03/05/2024 Education Undisputed 01/23/2026 1149932573 CMS
Travere Therapeutics, Inc. $24.38 03/05/2024 Food and Beverage Undisputed 01/23/2026 1149932577 CMS
Travere Therapeutics, Inc. $2.38 05/06/2024 Education Undisputed 01/23/2026 1149932562 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.